New insights into small‐cell lung cancer development and therapy

2020/04/13 by Yuwen Wang, Songyun Zou, Zhuyun Zhao +3
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer therapeutics and mechanisms #Lung Cancer Research Studies #Neuroendocrine Tumor Research Advances

paper · doi:10.1002/cbin.11359

openalex publication_date 2020/04/13 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases; however, it is characterized by easy relapse and low survival rate, leading to one of the most intractable diseases in clinical practice. Despite decades of basic and clinical research, little progress has been made in the management of SCLC. The current standard first-line regimens of SCLC still remain to be cisplatin or carboplatin combined with etoposide, and the adverse events of chemotherapy are by no means negligible. Besides, the immunotherapy on SCLC is still in an early stage and novel studies are urgently needed. In this review, we describe SCLC development and current therapy, aiming at providing useful advices on basic research and clinical strategy.

Citations

• Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide
• Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
• First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Related

• Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
• Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
• Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
• Precision Management of Advanced Non–Small Cell Lung Cancer
• Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis